USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...

In a further comparison using DPP-4i/SU as the reference, the GLP-1 RA/SGLT2i combination therapy had the greatest effect in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced risk for obesity-related ...

Evolv has launched a supplement featuring yeast engineered to produce a peptide that engages GLP-1 receptors, with a ...

Taiwan: A recent study has found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared with ...

Protective associations were seen between GLP-1 RA use and colon and rectal cancers. (HealthDay News) — For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are ...

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...

Jorge and colleagues focused on those whose records indicated they had SLE, with or without LN, and concomitant type 2 diabetes, who had started either a GLP-1 receptor agonist (n=910) or a DPP-4 ...

Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...